Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegozafermin (BIO89-100) Phase 1b/2a in NASH and NAFLD
NCT04048135Phase 2Completed
- Sponsor
- 89bio
- Start
- Jul 2019
- Primary completion
- Aug 2020
- Modality
- Carrier/Scaffold Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of pegozafermin in Nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), sponsored by 89bio. Started Jul 2019; status: completed.
02
Drugs
pegozafermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04048135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04048135.